PMID- 33805757
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 6
DP  - 2021 Mar 13
TI  - The Role of TNF-alpha and Anti-TNF-alpha Agents during Preconception, Pregnancy, and 
      Breastfeeding.
LID - 10.3390/ijms22062922 [doi]
LID - 2922
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a multifunctional Th1 cytokine and one of 
      the most important inflammatory cytokines. In pregnancy, TNF-alpha influences hormone 
      synthesis, placental architecture, and embryonic development. It was also shown 
      that increased levels of TNF-alpha are associated with pregnancy loss and 
      preeclampsia. Increased TNF-alpha levels in complicated pregnancy draw attention to 
      trophoblast biology, especially migratory activity, syncytialisation, and 
      endocrine function. Additionally, elevated TNF-alpha levels may affect the 
      maternal-fetal relationship by altering the secretory profile of placental 
      immunomodulatory factors, which in turn affects maternal immune cells. There is 
      growing evidence that metabolic/pro-inflammatory cytokines can program early 
      placental functions and growth in the first trimester of pregnancy. Furthermore, 
      early pregnancy placenta has a direct impact on fetal development and maternal 
      immune system diseases that release inflammatory (e.g., TNF-alpha) and 
      immunomodulatory factors, such as chronic inflammatory rheumatic, 
      gastroenterological, or dermatological diseases, and may result in an abnormal 
      release of cytokines and chemokines in syncytiotrophoblasts. Pregnancy poses a 
      challenge in the treatment of chronic disease in patients who plan to have 
      children. The activity of the disease, the impact of pregnancy on the course of 
      the disease, and the safety of pharmacotherapy, including anti-rheumatic agents, 
      in pregnancy should be considered.
FAU - Romanowska-Prochnicka, Katarzyna
AU  - Romanowska-Prochnicka K
AD  - Department of Biophysics and Human Physiology, Faculty of Health Sciences, Warsaw 
      Medical University, 02-091 Warsaw, Poland.
AD  - Department of Connective Tissue Diseases, National Institute of Geriatrics, 
      Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.
FAU - Felis-Giemza, Anna
AU  - Felis-Giemza A
AD  - Department of Connective Tissue Diseases, National Institute of Geriatrics, 
      Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.
FAU - Olesinska, Marzena
AU  - Olesinska M
AD  - Department of Connective Tissue Diseases, National Institute of Geriatrics, 
      Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.
FAU - Wojdasiewicz, Piotr
AU  - Wojdasiewicz P
AUID- ORCID: 0000-0003-3309-996X
AD  - Department of Biophysics and Human Physiology, Faculty of Health Sciences, Warsaw 
      Medical University, 02-091 Warsaw, Poland.
FAU - Paradowska-Gorycka, Agnieszka
AU  - Paradowska-Gorycka A
AUID- ORCID: 0000-0002-4249-3136
AD  - Department of Molecular Biology, National Institute of Geriatrics, Rheumatology 
      and Rehabilitation, 02-637 Warsaw, Poland.
FAU - Szukiewicz, Dariusz
AU  - Szukiewicz D
AUID- ORCID: 0000-0002-0124-060X
AD  - Department of Biophysics and Human Physiology, Faculty of Health Sciences, Warsaw 
      Medical University, 02-091 Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210313
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 91X1KLU43E (golimumab)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
RN  - UMD07X179E (Certolizumab Pegol)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/immunology/pathology
MH  - Breast Feeding
MH  - Certolizumab Pegol/therapeutic use
MH  - Etanercept/therapeutic use
MH  - Female
MH  - Gastritis/*drug therapy/immunology/pathology
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Humans
MH  - Infliximab/therapeutic use
MH  - Parturition/drug effects
MH  - Pregnancy
MH  - Pregnancy Trimester, First/*drug effects/immunology
MH  - Th1-Th2 Balance/drug effects
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
PMC - PMC7998738
OTO - NOTNLM
OT  - TNF-alpha
OT  - anti-TNF-alpha
OT  - breastfeeding
OT  - fertility
OT  - placental transfer
OT  - pregnancy
OT  - procreation
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/04 06:00
MHDA- 2021/04/24 06:00
PMCR- 2021/03/13
CRDT- 2021/04/03 01:21
PHST- 2021/02/19 00:00 [received]
PHST- 2021/03/11 00:00 [accepted]
PHST- 2021/04/03 01:21 [entrez]
PHST- 2021/04/04 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2021/03/13 00:00 [pmc-release]
AID - ijms22062922 [pii]
AID - ijms-22-02922 [pii]
AID - 10.3390/ijms22062922 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Mar 13;22(6):2922. doi: 10.3390/ijms22062922.